Toxic EncephalopathyNCT06798142
Risk Stratification and Heterogeneity for Organ Damage in Acute Diquat Poisoning
An observational study of Toxic Encephalopathy and Diquat Poisoning, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School at 1 site in China.
Trial summary
This ambispective cohort study aims to characterize the relationship between plasma diquat concentrations and organ damage risk. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Toxic Encephalopathy, Diquat Poisoning
- What is being tested?
- extracorporeal treatment
- Type of treatment
- Surgery or procedure
- How many people
- 193 participants
- Where
- 1 siteChina
- Study dates
- 1 Feb 2022to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with the history of acute diquat poisoning
Who may be able to join
- history of oral exposure to diquat solution reported by patient or proxy;
- a specimen for the diquat plasma concentration collected immediately upon admission;
- documentation that patients or, in case of unconsciousness of the patient, legal proxies were aware of and agreed to treatment plans.
Who cannot join
- they had ingested other toxins in addition to diquat (qualitative toxicological screening tests);
- diquat was not detected in specimens, or plasma concentration data were unavailable;
- patients with an exposure time (time from exposure to emergency department presentation) longer than 48 hours;
- data on organ damage were not unavailable;
- combined with other central nervous system injuries other than toxic encephalopathy.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Risk Stratification and Heterogeneity for Organ Damage in Acute Diquat Poisoning: A Multi-Center Cohort Study
This ambispective cohort study aims to characterize the relationship between plasma diquat concentrations and organ damage risk.
- Conditions
- Toxic Encephalopathy, Diquat Poisoning
- Being tested
- extracorporeal treatment
- Medical subject headings
- Neurotoxicity Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
extracorporeal treatmentProcedure or surgery
Extracorporeal treatments included hemoperfusion (HP) and continuous veno-venous hemodiafiltration (CVVHDF).
What is being measured
The primary outcome is the main question the study is designed to answer.
Survival outcome
Measured: 28 days within the index date of presentation at emergency department
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jan 2025
- Study start1 Feb 2022
- Primary completion30 Sep 2024
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Toxic EncephalopathyStudies of the same condition, open and under way.
- More trials run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 193 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hao Sun, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06798142
- Sponsor's protocol ID
- 2025-1047-02
- Status last verified
- Aug 2026
- First submitted
- 23 Jan 2025
- Last updated
- 18 Aug 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Risk Stratification and Heterogeneity for Organ Damage in Acute Diquat Poisoning: A Multi-Center Cohort Study
- ClinicalTrials.gov ID
- NCT06798142
- Acronym / sponsor ID
- 2025-1047-02
- Conditions
- Toxic Encephalopathy, Diquat Poisoning
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 193 participants (actual)
- Lead sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolUniversity, hospital or other
- Study start
- 1 Feb 2022 (actual)
- Primary completion
- 30 Sep 2024 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 29 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This ambispective cohort study aims to characterize the relationship between plasma diquat concentrations and organ damage risk.
Study design
- Observational model
- Cohort
- Time perspective
- Other
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with the history of acute diquat poisoning
Key inclusion criteria (3 listed)
- history of oral exposure to diquat solution reported by patient or proxy;
- a specimen for the diquat plasma concentration collected immediately upon admission;
- documentation that patients or, in case of unconsciousness of the patient, legal proxies were aware of and agreed to treatment plans.
Key exclusion criteria (5 listed)
- they had ingested other toxins in addition to diquat (qualitative toxicological screening tests);
- diquat was not detected in specimens, or plasma concentration data were unavailable;
- patients with an exposure time (time from exposure to emergency department presentation) longer than 48 hours;
- data on organ damage were not unavailable;
- combined with other central nervous system injuries other than toxic encephalopathy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| extracorporeal treatmentExtracorporeal treatments included hemoperfusion (HP) and continuous veno-venous hemodiafiltration (CVVHDF). | Procedure or surgery | – |
Primary outcome
Survival outcome
Time frame: 28 days within the index date of presentation at emergency department
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
Related trials for Toxic Encephalopathy
Not yet recruitingPhase 1
Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated Dyskinesia
Dyskinesia, Medication-induced, Dyskinesia, Drug-Induced
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Recruiting
Assessing DCog Short for Neurotoxicity in CAR-T
Neurotoxicity, Neurotoxicity Syndromes
Active, not recruitingPhase 3
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Brain and Central Nervous System Tumors, Neurotoxicity
Active, not recruiting
Table-Top Water Pitcher to Reduce Arsenic Exposure Among Well Users in New Hampshire
Arsenic Poisoning, Environmental Exposure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Toxic Encephalopathy and Diquat Poisoning, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Survival outcome (time frame: 28 days within the index date of presentation at emergency department). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.